tiprankstipranks
Rocket Pharma (RCKT)
NASDAQ:RCKT
US Market
RCKT
Rocket Pharmaceuticals
RESEARCH TOOLSreports
Want to see RCKT full AI Analyst Report?

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

1,714 Followers
See the Price Targets and Ratings of:

RCKT Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Rocket
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCKT Stock 12 Month Forecast

Average Price Target

$11.80
▲(201.79% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $11.80 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 201.79% change from the last price of $3.91.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","5":"$5","9":"$9","13":"$13","17":"$17"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5,9,13,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.42,4.387692307692308,5.355384615384615,6.323076923076924,7.2907692307692304,8.258461538461539,9.226153846153846,10.193846153846154,11.161538461538463,12.12923076923077,13.096923076923078,14.064615384615385,15.032307692307693,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.42,4.064615384615385,4.7092307692307696,5.353846153846154,5.998461538461539,6.643076923076924,7.287692307692308,7.932307692307693,8.576923076923077,9.221538461538461,9.866153846153846,10.510769230769231,11.155384615384616,{"y":11.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.42,3.926153846153846,4.432307692307692,4.938461538461539,5.444615384615385,5.950769230769231,6.456923076923077,6.963076923076923,7.469230769230769,7.975384615384615,8.481538461538461,8.987692307692308,9.493846153846153,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16.00Average Price Target$11.80Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on RCKT
Jason Zemansky
Bank of America Securities
Bank of America Securities
$10
Buy
155.75%
Upside
Reiterated
06/11/26
Bank of America Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TD Cowen Analyst forecast on RCKT
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/10/26
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
Chardan Capital Analyst forecast on RCKT
Geulah Livshits
Chardan Capital
Chardan Capital
$11
Buy
181.33%
Upside
Reiterated
05/10/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Rocket Pharmaceuticals (NASDAQ: RCKT)
LifeSci Capital Analyst forecast on RCKT
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$12
Buy
206.91%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Rocket Pharmaceuticals (NASDAQ: RCKT) and Evolent Health (NYSE: EVH)
Needham Analyst forecast on RCKT
Gil Blum
Needham
Needham
―
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA), Artivion (NYSE: AORT) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Wedbush Analyst forecast on RCKT
Yun Zhong
Wedbush
Wedbush
$16
Buy
309.21%
Upside
Reiterated
05/08/26
Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Canaccord Genuity Analyst forecast on RCKT
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$10
Buy
155.75%
Upside
Reiterated
05/07/26
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
J.P. Morgan Analyst forecast on RCKT
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)
Morgan Stanley Analyst forecast on RCKT
Michael Ulz
Morgan Stanley
Morgan Stanley
$5
Hold
27.88%
Upside
Reiterated
03/27/26
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
Goldman Sachs Analyst forecast on RCKT
Richard Law CFA
Goldman Sachs
Goldman Sachs
$4.69→$3
Sell
-23.27%
Downside
Reiterated
03/27/26
Analysts Conflicted on These Healthcare Names: Ascentage Pharma Group International Unsponsored ADR (NASDAQ: AAPG), Rocket Pharmaceuticals (NASDAQ: RCKT) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Leerink Partners Analyst forecast on RCKT
Mani Foroohar
Leerink Partners
Leerink Partners
$9→$11
Hold
181.33%
Upside
Assigned
03/27/26
Rocket Pharmaceuticals price target raised to $11 from $9 at LeerinkRocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Cantor Fitzgerald Analyst forecast on RCKT
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$8→$10
Buy
155.75%
Upside
Reiterated
02/27/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
William Blair Analyst forecast on RCKT
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (Other OTC: RMSYF) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Evercore ISI Analyst forecast on RCKT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$5
Hold
27.88%
Upside
Reiterated
12/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Novan (NASDAQ: NOVN) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Jefferies Analyst forecast on RCKT
Andrew Tsai
Jefferies
Jefferies
$2.5→$3
Hold
-23.27%
Downside
Reiterated
08/08/25
Jefferies Sticks to Its Hold Rating for Rocket Pharmaceuticals (RCKT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on RCKT
Jason Zemansky
Bank of America Securities
Bank of America Securities
$10
Buy
155.75%
Upside
Reiterated
06/11/26
Bank of America Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TD Cowen Analyst forecast on RCKT
Tara Bancroft
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/10/26
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
Chardan Capital Analyst forecast on RCKT
Geulah Livshits
Chardan Capital
Chardan Capital
$11
Buy
181.33%
Upside
Reiterated
05/10/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Rocket Pharmaceuticals (NASDAQ: RCKT)
LifeSci Capital Analyst forecast on RCKT
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$12
Buy
206.91%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Rocket Pharmaceuticals (NASDAQ: RCKT) and Evolent Health (NYSE: EVH)
Needham Analyst forecast on RCKT
Gil Blum
Needham
Needham
―
Hold
―
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA), Artivion (NYSE: AORT) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Wedbush Analyst forecast on RCKT
Yun Zhong
Wedbush
Wedbush
$16
Buy
309.21%
Upside
Reiterated
05/08/26
Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Canaccord Genuity Analyst forecast on RCKT
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$10
Buy
155.75%
Upside
Reiterated
05/07/26
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
J.P. Morgan Analyst forecast on RCKT
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (NASDAQ: RCKT) and Moderna (NASDAQ: MRNA)
Morgan Stanley Analyst forecast on RCKT
Michael Ulz
Morgan Stanley
Morgan Stanley
$5
Hold
27.88%
Upside
Reiterated
03/27/26
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
Goldman Sachs Analyst forecast on RCKT
Richard Law CFA
Goldman Sachs
Goldman Sachs
$4.69→$3
Sell
-23.27%
Downside
Reiterated
03/27/26
Analysts Conflicted on These Healthcare Names: Ascentage Pharma Group International Unsponsored ADR (NASDAQ: AAPG), Rocket Pharmaceuticals (NASDAQ: RCKT) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Leerink Partners Analyst forecast on RCKT
Mani Foroohar
Leerink Partners
Leerink Partners
$9→$11
Hold
181.33%
Upside
Assigned
03/27/26
Rocket Pharmaceuticals price target raised to $11 from $9 at LeerinkRocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Cantor Fitzgerald Analyst forecast on RCKT
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$8→$10
Buy
155.75%
Upside
Reiterated
02/27/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
William Blair Analyst forecast on RCKT
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (Other OTC: RMSYF) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Evercore ISI Analyst forecast on RCKT
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$5
Hold
27.88%
Upside
Reiterated
12/17/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Novan (NASDAQ: NOVN) and Rocket Pharmaceuticals (NASDAQ: RCKT)
Jefferies Analyst forecast on RCKT
Andrew Tsai
Jefferies
Jefferies
$2.5→$3
Hold
-23.27%
Downside
Reiterated
08/08/25
Jefferies Sticks to Its Hold Rating for Rocket Pharmaceuticals (RCKT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rocket Pharmaceuticals

3 Months
Geulah LivshitsChardan Capital
Success Rate
14/26 ratings generated profit
54%
Average Return
+8.39%
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +8.39% per trade.
1 Year
Greg HarrisonScotiabank
Success Rate
9/16 ratings generated profit
56%
Average Return
-0.97%
Copying Greg Harrison's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -0.97% per trade.
2 Years
Patrick DolezalLifeSci Capital
Success Rate
11/34 ratings generated profit
32%
Average Return
+12.88%
Copying Patrick Dolezal's trades and holding each position for 2 Years would result in 32.35% of your transactions generating a profit, with an average return of +12.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCKT Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
10
12
13
9
6
Buy
1
1
0
0
0
Hold
6
6
6
3
2
Sell
2
3
3
1
0
Strong Sell
0
0
0
0
0
total
19
22
22
13
8
In the current month, RCKT has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RCKT average Analyst price target in the past 3 months is 11.80.
Each month's total comprises the sum of three months' worth of ratings.

RCKT Financial Forecast

RCKT Earnings Forecast

Next quarter’s earnings estimate for RCKT is $1.04 with a range of $0.78 to $1.17. The previous quarter’s EPS was -$0.42. RCKT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RCKT has Performed in-line its overall industry.
Next quarter’s earnings estimate for RCKT is $1.04 with a range of $0.78 to $1.17. The previous quarter’s EPS was -$0.42. RCKT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RCKT has Performed in-line its overall industry.
No data currently available

RCKT Sales Forecast

Next quarter’s sales forecast for RCKT is $222.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. RCKT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RCKT has Performed in-line its overall industry.
Next quarter’s sales forecast for RCKT is $222.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. RCKT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RCKT has Performed in-line its overall industry.

RCKT Stock Forecast FAQ

What is RCKT’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharma’s 12-month average price target is 11.80.
    What is RCKT’s upside potential, based on the analysts’ average price target?
    Rocket Pharma has 201.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCKT a Buy, Sell or Hold?
          Rocket Pharma has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Rocket Pharma’s price target?
            The average price target for Rocket Pharma is 11.80. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $16.00 ,the lowest forecast is $10.00. The average price target represents 201.79% Increase from the current price of $3.91.
              What do analysts say about Rocket Pharma?
              Rocket Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of RCKT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.